摘要
目的:了解武汉地区2008～2010年口服抗糖尿病药(0ADs)使用情况及变化趋势。方法:采用用药金额排序法和限定日剂量法对武汉地区24家医院2008～2010年口服抗糖尿病药使用情况进行统计分析。结果:2008～2010年武汉地区口服抗糖尿病药总用药金额和用药频度逐年上升。销售金额排序前3位的是阿卡波糖、瑞格列奈和二甲双胍,其3年销售金额之和所占比例达61.80%;而用药频度(DDDs)排序前4位的是格列齐特、阿卡波糖、格列美脲和二甲双胍,其3年DDDs之和所占比例达63.79%。格列美脲、格列齐特以及二甲双胍的日均费用(DDC)较低,2010年分别为2.08、2.35和3.42元/d。结论:武汉地区医院口服抗糖尿病药用药结构较为合理、稳定。阿卡波糖和二甲双胍最为临床认可,而格列齐特等磺脲类药物因其较好的性价比仍占重要地位。
Objective：To investigate the status of consumptions and developmental tendency of oral antidiabetic drugs（OADs） in Wuhan area from 2008 to 2010.Methods：With the analytical method of the Defined Daily Dose（DDD） recommended by WHO,the relative data of OADs used in 24 hospitals of Wuhan area during the period of 2008-2010 were statistically analyzed.Results：The consumption sum and frequency of drug use of OADs increased year by year.Top 3 OADs in the list of consumption sum were acarbose,repaglinide and metformin as the sum of consumption in the 3 years occupid 61.8%The most frequently used drugs were gliclazide,acarbose,glimepiride and metformin as the sum of the defined daily drugs system（DDDs） occupied 63.79%.Among the drugs listed above,gliclazide,glimepiride and metformin had the lowest daily drug cost（DDC） in 2010 with the costs of 2.08,2.35 and 3.42 yuan per day respectively.Conclusion： The application of OADs in Wuhan was rational and stable.Acarbose and metformin were the most popular drugs in the clinic.The sulphanylureas drugs such as gliclazide still took the important place in the therapy of diabetes because of their good performance of efficacy and cost
出处
《药物流行病学杂志》
CAS
2012年第2期85-90,共6页
Chinese Journal of Pharmacoepidemiology
